286 related articles for article (PubMed ID: 35770338)
1. Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome.
Liu J; Zhang L; Tian Y; Wan S; Hu M; Song S; Zhang M; Zhou Q; Xia Y; Wang X
J Cell Mol Med; 2022 Aug; 26(15):4357-4370. PubMed ID: 35770338
[TBL] [Abstract][Full Text] [Related]
2. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.
Bertolaccini ML; Contento G; Lennen R; Sanna G; Blower PJ; Ma MT; Sunassee K; Girardi G
J Autoimmun; 2016 Dec; 75():30-38. PubMed ID: 27160365
[TBL] [Abstract][Full Text] [Related]
3. Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis.
Dong Y; Lu Y; Xia Y; Wang X
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7084-7092. PubMed ID: 34182874
[TBL] [Abstract][Full Text] [Related]
4. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function.
Albert CR; Schlesinger WJ; Viall CA; Mulla MJ; Brosens JJ; Chamley LW; Abrahams VM
Am J Reprod Immunol; 2014 Feb; 71(2):154-64. PubMed ID: 24325143
[TBL] [Abstract][Full Text] [Related]
5. The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome.
Fierro JJ; Velásquez-Berrío M; Ospina A; Henning S; de Leeuw K; Cadavid J ÁP
Rheumatol Int; 2024 Feb; 44(2):223-234. PubMed ID: 37741812
[TBL] [Abstract][Full Text] [Related]
6. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.
Gerde M; Ibarra E; Mac Kenzie R; Fernandez Suarez C; Heer C; Alvarez R; Iglesias M; Balparda J; Beruti E; Rubinstein F
Thromb Res; 2021 Oct; 206():104-110. PubMed ID: 34454240
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Khizroeva J; Bitsadze V; Tincani A; Makatsariya A; Arslanbekova M; Babaeva N; Tsibizova V; Shkoda A; Makatsariya N; Tretyakova M; Solopova A; Gadaeva Z; Vorobev A; Khamani I; Aslanova Z; Nakaidze I; Mischenko A; Grigoreva K; Kunesko N; Egorova E; Mashkova T
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6157-6164. PubMed ID: 34044735
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies.
Marchetti T; Ruffatti A; Wuillemin C; de Moerloose P; Cohen M
J Thromb Haemost; 2014 Jun; 12(6):910-20. PubMed ID: 24656088
[TBL] [Abstract][Full Text] [Related]
9. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL].
Mekinian A; Vicaut E; Cohen J; Bornes M; Kayem G; Fain O
Gynecol Obstet Fertil Senol; 2018; 46(7-8):598-604. PubMed ID: 30041771
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Sciascia S; Branch DW; Levy RA; Middeldorp S; Pavord S; Roccatello D; Ruiz-Irastorza G; Tincani A; Khamashta M; Schreiber K; Hunt BJ
Thromb Haemost; 2016 Jan; 115(2):285-90. PubMed ID: 26421409
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Latino JO; Udry S; Aranda F; Wingeyer SP; Romero DSF; Belizna C; Larrañaga G
Lupus; 2020 Nov; 29(13):1736-1742. PubMed ID: 32838621
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy and Antiphospholipid Syndrome.
Schreiber K; Hunt BJ
Semin Thromb Hemost; 2016 Oct; 42(7):780-788. PubMed ID: 27652601
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome.
Arachchillage DJ; Laffan M; Pericleous C
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674847
[TBL] [Abstract][Full Text] [Related]
14. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.
Hooper A; Bacal V; Bedaiwy MA
Am J Reprod Immunol; 2023 Sep; 90(3):e13761. PubMed ID: 37641373
[TBL] [Abstract][Full Text] [Related]
15. Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?
Meroni PL
J Autoimmun; 2016 Dec; 75():1-5. PubMed ID: 27496152
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
Rand JH; Wu XX; Quinn AS; Chen PP; Hathcock JJ; Taatjes DJ
Blood; 2008 Sep; 112(5):1687-95. PubMed ID: 18577708
[TBL] [Abstract][Full Text] [Related]
17. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
De Carolis S; Botta A; Salvi S; di Pasquo E; Del Sordo G; Garufi C; Lanzone A; De Carolis MP
Autoimmun Rev; 2015 Sep; 14(9):760-2. PubMed ID: 25936295
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
Lefkou E; Varoudi K; Pombo J; Jurisic A; Jurisic Z; Contento G; Girardi G
Biochem Pharmacol; 2020 Dec; 182():114217. PubMed ID: 32926874
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases.
Alijotas-Reig J; Esteve-Valverde E; Llurba E; Gris JM
Semin Arthritis Rheum; 2019 Oct; 49(2):314-318. PubMed ID: 30824278
[TBL] [Abstract][Full Text] [Related]
20. Managing antiphospholipid syndrome in pregnancy.
Schreiber K; Hunt BJ
Thromb Res; 2019 Sep; 181 Suppl 1():S41-S46. PubMed ID: 31477227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
